Wenqing Zhang, Ying Sun, Lei Liu, Zongpeng Li
Department of Geriatrics, Yidu Central Hospital of Weifang, Weifang, Shandong, China (mainland)
Med Sci Monit 2017; 23:4506-4512
TNFR-associated factor 1 (TRAF1) and TRAF2 have been demonstrated to inhibit apoptosis and promote cell survival in glioblastoma (GBM) cells with experiments in vitro. However, their clinical and prognostic significance have not been elucidated.
MATERIAL AND METHODS: In our study, we for the first time investigated the expression of TRAF1 and TRAF2 in 105 GBM tissues. Furthermore, we evaluated their clinical significance, including their association with clinicopathologic factors and prognostic value. The association with clinicopathologic factors was assessed by chi-square test. The relation of TRAF1/2 expression to survival rate was assessed by Kaplan-Meier method and Cox-regression model.
RESULTS: We demonstrated that TRAF1 expression had no significant prognostic value for GBM. On the contrary, high expression of TRAF2 can predict poorer prognosis of GBM and was identified as an independent biomarker in GBM prognosis.
CONCLUSIONS: High expression of TRAF2 was identified as an independent biomarker in GBM prognosis, indicating TRAF2 as a novel drug target in GBM treatment.
Keywords: Biological Markers, Glioblastoma, Prognosis, TNF Receptor-Associated Factor 1, TNF Receptor-Associated Factor 2